Generalized Pustular Drug Rash Induced by Hydroxychloroquine

M. LOTEM, A. INGBER, R. SEGAL and M. SANDBANK

Department of Dermatology, Beilinson Medical Center, Petah Tiqva and Sackler School of Medicine, Tel Aviv University, Israel

A 69-year-old man developed a generalized pustular drug rash 2 weeks after starting on hydroxychloroquine sulfate (HCQ) medication. This form of drug eruption had not previously been attributed to HCQ, although a diagnosis of pustular psoriasis cannot be ruled out. Key words: Generalized pustulosis; Drug eruption.

(Accepted October 27, 1989.)

Acta Derm Venereol (Stockh) 1990; 70: 250–251.

M. Lotem, Department of Dermatology, Beilinson Medical Center, Petah Tiqva 49 100, Israel.

Hydroxychloroquine sulfate (HCQ) is an acceptable agent for a variety of skin diseases, in addition to its antimalarial properties. Like the parent molecule, chloroquine, cutaneous side effects include generalized pruritus, pigmented changes of skin, mucosae, hair and nails, lichenoid and morbilliform eruptions and uncommonly fixed drug eruption and erythema annulare centrifugum. We describe here a patient treated with HCQ for pemphigus erythematosus who developed a generalized subcorneal pustular rash 3 weeks after initiation of therapy.

CASE PRESENTATION

A 69-year-old man had been suffering from pemphigus erythematosus for 5 years. This diagnosis was based on typical skin lesions associated with the histology and immunofluorescence of superficial pemphigus. Since it was impossible to reduce his maintenance dose of prednisone to less than 15 mg per day, HCQ (Plaquenil)® 200 mg/day was added as an adjuvant therapy. Other medications which the patient was taking included quinidine bisulfate 500 mg/day and isosorbide dinitrate 10 mg/day for ischemic heart disease.

Two weeks after initiation of HCQ, erythematosus patches developed with predilection to the trunk and flexures which were soon covered with multiple small pustules, partly in a circular arrangement. The eruption was accompanied by a systemic fever, mild leukocytosis and negative cultures of pustule contents. A skin biopsy revealed subcorneal accumulations of neutrophils with mild perivascular lymphocytic infiltration around blood vessels in the dermis. There was no evidence of acantholysis.

On admission, HCQ was stopped and prednisone was raised to 80 mg/day without improvement and then to 120 mg/day. It took 4 weeks for clearing of the skin to become evident. The prednisone dose was then reduced gradually to 10 mg/day. During this whole period, the preceding skin lesions of pemphigus erythematosus were completely unaffected by the newly developed eruption. During the year following this episode, no further skin lesions appeared. For obvious reasons, HCQ has not been prescribed again.

DISCUSSION

Although the histological picture of our patient's skin lesions was suggestive of subcorneal pustular dermatosis, subcorneal pustulosis is a synonym for 'subcorneal pustular dermatosis' in the absence of the typical clinical features and course. Similarly, there is no basis for a diagnosis of pemphigus foliaceus in the absence of acantholysis.

There are well established observations that psoriasis is worsened by antimalarials in general (1) and by HCQ in particular (2). It takes the form of a generalized erythroderma or extension of plaques. There was one report of a generalized pustular psoriasis during HCQ medication in a man assumed to have had psoriasis previously (3). In our patient, generalized pustular psoriasis cannot be ruled out, although the lack of history or future development of psoriasis and the unyielding nature of eruption to administration of corticosteroids do not favour this diagnosis.

Generalized pustulosis as a form of drug eruption is a rare yet a known entity (Table 1, refs. 5–9). Searching the literature, we found a previous description of a generalized pustular rash during anti-

Table 1. Drugs associated with a generalized pustular rash

<table>
<thead>
<tr>
<th>Drug</th>
<th>Ref.</th>
<th>Drug</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amoxicillin</td>
<td>(4)</td>
<td>Chloramphenicol</td>
<td>(8)</td>
</tr>
<tr>
<td>Cefazolin</td>
<td>(5)</td>
<td>Diltiazem</td>
<td>(9)</td>
</tr>
<tr>
<td>Cefalexin</td>
<td>(6)</td>
<td>Fusid</td>
<td>(8)</td>
</tr>
<tr>
<td>Cephadrine</td>
<td>(7)</td>
<td>Pyrimethamine</td>
<td>(8)</td>
</tr>
</tbody>
</table>

Acta Derm Venereol (Stockh) 70
malarial therapy, although not regarded as such (8). We suggest that this etiology could account for our patient’s eruption. The combination of HCQ with another quinine (quinidine bisulfate) that the patient was taking could have had an auxiliary effect for inducing this adverse reaction.

REFERENCES

Sézary-type Cutaneous T-cell Leukaemia
Response to Winkelmann Regimen

C. C. HARLAND,1 M. BALSITIS2 and L. G. MILLARD1
Departments of 1Dermatology and 2Histopathology, University Hospital, Nottingham, England

A 37-year-old woman presented with an aggressive leukemic form of small T-cell Sézary syndrome. Despite this unusually malignant variant of the disease, there was a dramatic response to a modified Winkelmann regimen of chlorambucil and prednisolone, and a useful, sustained remission of 7 months. The Winkelmann regimen remains an important and relatively non-toxic chemotherapeutic option for palliation of advanced Sézary syndrome.

(Accepted September 25, 1989.)
C. C. Harland, Department of Dermatology, University Hospital, Queens Medical Centre, Nottingham, NG7 2UH, England.

Sézary syndrome is an erythrodermic variant of mycosis fungoides with circulating malignant cerebri-form T-cells and both belong to the general category of cutaneous T-cell lymphoma (CTCL). Mortality rates differ, but poor-risk patients with visceral involvement have a median survival of 2.5 years (1). Patients die as a result of florid progression of widely disseminated disease, infection, or complications of treatment. Indeed, aggressive treatment of advanced disease is associated with high morbidity and mortality (2).

A patient who presented with advanced leukaemic phase of Sézary syndrome was treated with a modified version of the Winkelmann regimen (3). Her social circumstances precluded multiple, toxic chemotherapeutic regimens which might entail prolonged hospital admission and concomitant risk of complications.

CASE REPORT
A 37-year-old woman developed a generalized and intensely pruritic eruption over 4 months. She was divorced and unemployed and had three children. On presentation the patient was ill with erythroderma, diffuse cutaneous induration, exoriation, crusting, subtotal alopecia, lymphadenopathy and hepatosplenomegaly (Fig. 1a). She was admitted for investigation with the following abnormal laboratory findings: haemoglobin 10.3 g/dl, platelet count 441x10^5/l, white cell count 444x10^9/l; bone marrow aspirate contained abundant small cells with convoluted nuclei. Serum gamma glutamyl transferase 68 IU/l, alkaline phos-